<DOC>
	<DOCNO>NCT01703624</DOCNO>
	<brief_summary>This investigation beneficial effect , tolerability safety range single dose orally inhaled glycopyrronium bromide ( PSX1002GB pMDI ) male female patient moderate severe chronic obstructive pulmonary disease ( COPD ) . COPD long term progressive disease lung , generally cause cigarette smoking , factor may involve . Glycopyrronium bromide ( GB ) appear particularly useful dilate constricted airway patient , duration action variously describe 12 24 hour . This study investigate well tolerated safe medication range dos . It also help selection suitable dose large repeat dose study , base measure lung response . It also help determine often medication give ; twice daily , daily . Up 40 patient enrol study , range age 40 75 year age . Patients medically assessed participation ensure suitability . The study take place one centre UK five session ; session one dose ( 2 puff ) GB one dose ( 2 puff ) placebo administer simple inhaler device . Neither staff patient know dose , placebo , take . Lung function measure 26 hour administration dose use standard spirometry equipment . Blood sample take 24-hour period check blood level GB . There period week dose session . Patients medically review study confirm untoward effect present .</brief_summary>
	<brief_title>Dose Ranging Study Glycopyrronium Bromide Patients With Moderate Severe Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>Male female age 4075 year , inclusive A clinical diagnosis moderate severe COPD ( GOLD guideline ) Current smokers exsmokers least 10pack year smoke history Postbronchodilator FEV1/FVC ratio &lt; 70 % Screen Postbronchodilator FEV1 ≥ 40 % &lt; 80 % predict Screen Demonstrated responsive ipratropium ( define least 100ml increase FEV1 follow ipratropium 80 µg ) Ability perform acceptable spirometry ( ATS/ERS guideline ) Willing able provide write informed consent Females pregnant lactate Screening Visit , childbearing potential use acceptable mean birth control throughout study ( define protocol ) Current evidence recent history clinically significant disease ( COPD ) abnormality opinion Investigator would put subject risk would compromise quality study data ( define protocol ) Recent history hospitalisation due exacerbation airway disease within three month prior Screening Visit randomisation Need increase treatment COPD within six week prior Screening Visit randomisation Primary diagnosis asthma Prior lung volume reduction surgery history chest/lung irradiation Regular use daily oxygen therapy Use systemic steroid within three month prior Screening Visit runin period Respiratory tract infection within six week prior Screening Visit . History tuberculosis , bronchiectasis nonspecific pulmonary disease History urinary retention bladder neck obstructive type symptom History narrowangle glaucoma Clinically significant abnormal ECG Positive Hepatitis B antigen positive Hepatitis C antibody Positive screen test HIV antibody Current evidence history excessive use abuse alcohol opinion Investigator Current evidence history abuse legal drug use illegal drug substance opinion Investigator Donation 450 ml blood within eight week Screening Visit History hypersensitivity intolerance aerosol medication Participation another investigational drug study drug receive within 30 day prior Screening Visit . Inability comply study procedure study treatment intake , include inability train and/or inability demonstrate good inhaler technique Vitalograph AIM</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>glycopyrronium bromide</keyword>
	<keyword>glycopyrrolate</keyword>
	<keyword>oral inhalation</keyword>
	<keyword>COPD</keyword>
	<keyword>chronic obstructive pulmonary disease</keyword>
	<keyword>lung function</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>tolerability</keyword>
	<keyword>safety</keyword>
	<keyword>cross-over</keyword>
	<keyword>single-dose</keyword>
	<keyword>dose-ranging</keyword>
</DOC>